245 related articles for article (PubMed ID: 7975844)
1. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus.
Sutter G; Wyatt LS; Foley PL; Bennink JR; Moss B
Vaccine; 1994 Aug; 12(11):1032-40. PubMed ID: 7975844
[TBL] [Abstract][Full Text] [Related]
2. Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge.
Lawson CM; Bennink JR; Restifo NP; Yewdell JW; Murphy BR
J Virol; 1994 Jun; 68(6):3505-11. PubMed ID: 7514677
[TBL] [Abstract][Full Text] [Related]
3. Nonreplicating vaccinia vector efficiently expresses recombinant genes.
Sutter G; Moss B
Proc Natl Acad Sci U S A; 1992 Nov; 89(22):10847-51. PubMed ID: 1438287
[TBL] [Abstract][Full Text] [Related]
4. Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination.
Breathnach CC; Rudersdorf R; Lunn DP
Vet Immunol Immunopathol; 2004 Apr; 98(3-4):127-36. PubMed ID: 15010222
[TBL] [Abstract][Full Text] [Related]
5. Cell-mediated immune responses to influenza virus antigens expressed by vaccinia virus recombinants.
Andrew ME; Coupar BE; Ada GL; Boyle DB
Microb Pathog; 1986 Oct; 1(5):443-52. PubMed ID: 3509883
[TBL] [Abstract][Full Text] [Related]
6. Characterization of antibody and cytotoxic T lymphocyte responses to human influenza virus H3 haemagglutinin expressed from the haemagglutinin locus of vaccinia virus.
Itamura S; Iinuma H; Shida H; Morikawa Y; Nerome K; Oya A
J Gen Virol; 1990 Dec; 71 ( Pt 12)():2859-65. PubMed ID: 2273387
[TBL] [Abstract][Full Text] [Related]
7. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine.
Ramírez JC; Gherardi MM; Esteban M
J Virol; 2000 Jan; 74(2):923-33. PubMed ID: 10623755
[TBL] [Abstract][Full Text] [Related]
8. No recognition of MHC class II+ cells infected with a vaccinia virus encoding influenza type A nucleoprotein by class II-restricted T cells.
Freer G; Senesi S
Immunol Lett; 1993 Jun; 36(3):305-12. PubMed ID: 8370602
[TBL] [Abstract][Full Text] [Related]
9. Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells.
Bennink JR; Yewdell JW; Smith GL; Moller C; Moss B
Nature; 1984 Oct 11-17; 311(5986):578-9. PubMed ID: 6332992
[TBL] [Abstract][Full Text] [Related]
10. Homotypic and heterotypic protection against influenza virus infection in mice by recombinant vaccinia virus expressing the haemagglutinin or nucleoprotein of influenza virus.
Endo A; Itamura S; Iinuma H; Funahashi S; Shida H; Koide F; Nerome K; Oya A
J Gen Virol; 1991 Mar; 72 ( Pt 3)():699-703. PubMed ID: 2005435
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.
Ober BT; Brühl P; Schmidt M; Wieser V; Gritschenberger W; Coulibaly S; Savidis-Dacho H; Gerencer M; Falkner FG
J Virol; 2002 Aug; 76(15):7713-23. PubMed ID: 12097585
[TBL] [Abstract][Full Text] [Related]
12. Protective immunity against influenza in HLA-A2 transgenic mice by modified vaccinia virus Ankara vectored vaccines containing internal influenza proteins.
Di Mario G; Sciaraffia E; Facchini M; Gubinelli F; Soprana E; Panigada M; Bernasconi V; Garulli B; Siccardi A; Donatelli I; Castrucci MR
Pathog Glob Health; 2017 Mar; 111(2):76-82. PubMed ID: 28079473
[TBL] [Abstract][Full Text] [Related]
13. Non-replicating vaccinia vector efficiently expresses bacteriophage T7 RNA polymerase.
Sutter G; Ohlmann M; Erfle V
FEBS Lett; 1995 Aug; 371(1):9-12. PubMed ID: 7664891
[TBL] [Abstract][Full Text] [Related]
14. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus.
Wang Z; La Rosa C; Maas R; Ly H; Brewer J; Mekhoubad S; Daftarian P; Longmate J; Britt WJ; Diamond DJ
J Virol; 2004 Apr; 78(8):3965-76. PubMed ID: 15047812
[TBL] [Abstract][Full Text] [Related]
15. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
16. Protein and modified vaccinia virus Ankara-based influenza virus nucleoprotein vaccines are differentially immunogenic in BALB/c mice.
Altenburg AF; Magnusson SE; Bosman F; Stertman L; de Vries RD; Rimmelzwaan GF
Clin Exp Immunol; 2017 Oct; 190(1):19-28. PubMed ID: 28665497
[TBL] [Abstract][Full Text] [Related]
17. Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines.
Meseda CA; Atukorale V; Kuhn J; Schmeisser F; Weir JP
PLoS One; 2016; 11(2):e0149364. PubMed ID: 26895072
[TBL] [Abstract][Full Text] [Related]
18. Vaccinia virus serpins B13R and B22R do not inhibit antigen presentation to class I-restricted cytotoxic T lymphocytes.
Blake NW; Kettle S; Law KM; Gould K; Bastin J; Townsend AR; Smith GL
J Gen Virol; 1995 Sep; 76 ( Pt 9)():2393-8. PubMed ID: 7561783
[TBL] [Abstract][Full Text] [Related]
19. Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses.
Baur K; Brinkmann K; Schweneker M; Pätzold J; Meisinger-Henschel C; Hermann J; Steigerwald R; Chaplin P; Suter M; Hausmann J
J Virol; 2010 Sep; 84(17):8743-52. PubMed ID: 20538860
[TBL] [Abstract][Full Text] [Related]
20. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses.
Altstein AD; Gitelman AK; Smirnov YA; Piskareva LM; Zakharova LG; Pashvykina GV; Shmarov MM; Zhirnov OP; Varich NP; Ilyinskii PO; Shneider AM
Arch Virol; 2006 May; 151(5):921-31. PubMed ID: 16292596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
